RT Journal Article
SR Electronic
T1 Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.25.20237883
DO 10.1101/2020.11.25.20237883
A1 Ray, Yogiraj
A1 Paul, Shekhar Ranjan
A1 Bandopadhyay, Purbita
A1 D’Rozario, Ranit
A1 Sarif, Jafar
A1 Lahiri, Abhishake
A1 Bhowmik, Debaleena
A1 Vasudevan, Janani Srinivasa
A1 Maurya, Ranjeet
A1 Kanakan, Akshay
A1 Sharma, Sachin
A1 Kumar, Manish
A1 Singh, Praveen
A1 Roy, Rammohan
A1 Chaudhury, Kausik
A1 Maiti, Rajsekhar
A1 Bagchi, Saugata
A1 Maiti, Ayan
A1 Perwez, Md. Masoom
A1 Mondal, Abhinandan
A1 Tewari, Avinash
A1 Mandal, Samik
A1 Roy, Arpan
A1 Saha, Moumita
A1 Biswas, Durba
A1 Maiti, Chikam
A1 Chakraborty, Sayantan
A1 Sarkar, Biswanath Sharma
A1 Haldar, Anima
A1 Saha, Bibhuti
A1 Sengupta, Shantanu
A1 Pandey, Rajesh
A1 Chatterjee, Shilpak
A1 Bhattacharya, Prasun
A1 Paul, Sandip
A1 Ganguly, Dipyaman
YR 2020
UL http://medrxiv.org/content/early/2020/11/29/2020.11.25.20237883.abstract
AB Introduction A single center open label phase II randomised control trial was done to assess the pathogen and host-intrinsic factors influencing clinical and immunological benefits of passive immunization using convalescent plasma therapy (CPT), in addition to standard of care (SOC) therapy in severe COVID-19 patients, as compared to patients only on SOC therapy.Methods Convalescent plasma was collected from patients recovered from COVID-19 following a screening protocol which also included measuring plasma anti SARS-CoV2 spike IgG content. Retrospectively, neutralizing antibody content was measured and proteome was characterized by LC-MS/MS for all convalescent plasma units that were transfused to patients. Severe COVID-19 patients with evidence for acute respiratory distress syndrome (ARDS) with PaO2/FiO2 ratio 100-300 (moderate ARDS) were recruited and randomised into two parallel arms of SOC and CPT, N=40 in each arm. Peripheral blood samples were collected on the day of enrolment (T1) followed by day3/4 (T2) and day 7 (T3). RT-PCR and sequencing was done for SARS-CoV2 RNA isolated from nasopharyngeal swabs collected at T1. A panel of cytokines and neutralizing antibody content were measured in plasma at all three timepoints. Patients were followed up for 30 days post-admission to assess the primary outcomes of all cause mortality and immunological correlates for clinical benefits.Results While across all age-groups no statistically significant clinical benefit was registered for patients in the CPT arm, significant immediate mitigation of hypoxia, reduction in hospital stay as well as survival benefit was recorded in severe COVID-19 patients with ARDS aged less than 67 years receiving convalescent plasma therapy. In addition to its neutralizing antibody content a prominent effect of convalescent plasma on attenuation of systemic cytokine levels possibly contributed to its benefits.Conclusion Precise targeting of severe COVID-19 patients is necessary for reaping the clinical benefits of convalescent plasma therapy.Clinical trial registration Clinical Trial Registry of India No. CTRI/2020/05/025209Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinical Trial Registry of India No. CTRI/2020/05/025209Funding StatementD.G. acknowledges funding for the RCT and associated immune monitoring studies from Council of Scientitific Industrial Research (CSIR), Govt. of India (MLP-129); R.P. acknowledge funding from CSIR (MLP-2005) and Fondation Botnar.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The randomized control trial (RCT) on passive immunization with convalescent plasma therapy and all associated studies were done with informed consent from the patients according to the recommendations and ethical approval from the Institutional Review Boards of all the concerned institutions, viz. CSIR-Indian Institute of Chemical Biology, Kolkata, India (IICB/IRB/2020/3P), Medical College Hospital, Kolkata (MC/KOL/IEC/NON-SPON/710/04/2020), India and Infectious Disease & Beleghata General Hospital (ID & BG Hospital), Kolkata, India (IDBGH/Ethics/2429). The RCT was approved by Central Drugs Standard Control Organisation (CDSCO) under Directorate General of Health Services, Ministry of Health & Family Welfare, Govt. of India (approval no. CT/BP/09/2020) and registered with Clinical Trial Registry of India (CTRI, No. CTRI/2020/05/025209), under Indian Council of Medical Research, India.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the manuscript are available with the corresponding author.